Introduction
Visceral leishmaniasis in Europe is a disease caused by the protozoan pathogen Leishmania infantum that affects all countries of the Mediterranean region. The disease has a low prevalence in humans -the definitive host -but not in dogs, which act as reservoirs of the parasite. The risk of human disease significantly increased in immunosuppressed individuals mainly linked to HIV, but due to highly active antiretroviral therapies its presence has dramatically decreased [1] . Current pharmacopoeia against leishmaniasis includes old-fashioned pentavalent antimonium derivatives, as well as amphotericin B, paromomycin and alkylphospholipids [2] . Most of them have many undesirable side effects or require parental administration and longterm treatments, which can make treatment difficult to adhere to [3] .
Searching for differentiable targets between the host and pathogen is a recognized strategy for designing new drugs. Type IB DNA topoisomerases (TopIB) were indicated as putative targets in proliferative processes when their mechanism of action was originally shown [4] . Since then, numerous compounds have shown antiproliferative effects: (i) by interfering with the catalytic properties of enzymes (TopIB inhibitors) or (ii) by stabilizing the enzyme-DNA complex -a transient step of all Top activities -that can be hindered in time by many compounds (TopIB poisons). TopIB poisons prevent the religation step and produces single DNA breaks that interfere with the replication fork of the dividing cells [5] . An amazing result found in 2003 was that L. infantum TopIB (LiTopIB) was a heterodimeric enzyme encoded by two genes that were placed on different chromosomes [6] . This characteristic is only shared by certain phylogenetically close microorganisms such as Trypanosoma cruzi and T. brucei [7] . Despite these differences, most of the domains related to the enzymatic activity are conserved between both subunits, which are interconnected by two polypeptide extensions that play the role of a putative linker. This region is not needed for TopIB activity, but it contributes to DNA binding and camptothecin inhibition, theoretically by slowing down the religation step of the nicking-closing reaction [8] [9] [10] .
Camptothecin and derivatives, known as TopIB poisons, develop their function by binding in a specific and reversible manner to the transient DNA-enzyme complexes [11] . These drugs effectively target the TopIB-DNA binary complex, while they do not bind to the enzyme alone and display a weak affinity for DNA in the absence of the enzyme [12] . The presence of cleavage complexes generates collisions with the replication fork, causing DNA breaks by converting transient complexes to permanent strand damage and consequently making these compounds powerful anticancer drugs. Camptothecin in fact shows a remarkable antiproliferative potential in vitro against a wide range of tumor cells in the submicromolar range [13, 14] and it has been the first compound described as a specific inhibitor of eukaryotic cell TopIB with no effect on the bacterial TopIA and a well-defined mechanism of action. The development of camptothecin derivatives against several types of cancer has resulted in two watersoluble compounds currently used in clinical practice: topotecan (Hycantim
1
) and the pro-drug irinotecan (Camptosar 1 ). In addition a third compound, gimatecan (ST1481) is an orphan drug that is being studied in clinical phase II against astrocytoma, glioblastoma and oligodendroglial tumors [15] .
TopIB is essential for DNA replication, recombination and repair mechanisms. Most organisms are unable to survive in the absence of this enzyme [16] . Previous works have unsuccessfully tried to create Leishmania [17] or T. brucei [18] strains lacking the small monomer or both protomers, respectively. For these reasons and because of distinct structural differences between human and leishmanial TopIB, this protein is considered a valuable target for chemotherapy [19] . This paper explains the effect of these camptothecin derivatives on an ex vivo murine model of infected splenocytes with L. infantum. Furthermore, the in vitro effect of these compounds reveals for the first time their ability to trap TopIB-DNA covalent complexes on Leishmania parasites, thus preventing the religation step at micromolar concentrations.
Materials and methods

Reagents and culture media
Pyrococcus furiosus (Pfu), klenow polymerases and restriction enzymes were acquired from Roche (Roche Farma SA, Spain) and GE Healthcare (Spain). T4 DNA ligase was obtained from Stratagene (La Jolla, CA, USA). Cell culture media, camptothecin, irinotecan and SN-38 were purchased from Sigma (Sigma-Aldrich, Spain). Topotecan (Hycantim 1 ) was obtained from GlaxoSmithKline (UK). Gimatecan and camptothecin-N-oxide were kind gifts of Sigma Tau to Alessandro Desideri. Primers for PCR amplification were from Sigma Genosys (UK).
Biological material
L. infantum-IFP1.4 promastigotes and infecting amastigotes were obtained by stable transfection of L. infantum (BCN-150 strain) with the pLEXSY-IFP1.4 vector [20] . This vector contains the 987 bp ORF region of the infrared fluorescent protein 1.4 (IFP1.4) derived from Discosoma sp., [21] kindly provided by Dr. Roger Y. Tsien (Department of Pharmacology; Department of Chemistry and Biochemistry, University of California, San Diego, USA).
To obtain naturally amastigote-infected splenocytes cultures, BALB/c mice were inoculated intraperitoneally with 10 8 L.
infantum-IFP1.4 purified metacyclic promastigotes [22] . Five weeks post-infection spleens were aseptically dissected and infected splenocytes were cultured as described previously [20] . Different concentrations of miltefosine (included as positive control) and camptothecin derivatives were administered to the explants for 48 h. The viability of infecting amastigotes was assessed registering the fluorescence emission at 708 nm in an Odyssey (Li-Cor) infrared imaging system. To determine the cytotoxicity of the drugs in mammalian cells, the Alamar Blue staining method was used on drug-exposed splenocytes derived from uninfected mice, according to manufacturer's recommendations. The animal research described in this manuscript complied with Spanish (Ley 32/2007) and European Union Legislation (2010/ 63/UE). The used protocols were approved by the Animal Care Committee of Universidad de Leó n (Spain).
DNA relaxation assays
Cloning of LiTopIB ORFs (encoding large and small subunits), expression and purification of the enzyme were carried out as previously described [9] . TopIB activity was assayed by the relaxation of negatively supercoiled plasmid DNA. The reaction mixture, in a total volume of 20 mL, contained 0.5 mg of supercoiled DNA from the pBluescript SK(À) phagemid (pSK), 10 mM Tris-HCl buffer pH 7.5, 5 mM MgCl 2 , 0.1 mM EDTA, 15 mg/mL bovine serum albumin, 50 mM KCl, 1 unit of the leishmanial enzyme and 1 mL of the tested drugs at different concentrations (dose dependent) or at a fixed drug concentration (75 mM) at different time points ranging from 0.2 to 15 min (time-course). Reaction mixtures were incubated at 37 8C. Enzyme reactions were stopped by the addition of up to 1% SDS (w/v) (final concentration) and digested with 1 mg/mL proteinase K at 37 8C during one extra hour to remove protein that remained attached to the DNA fragments. The extent of plasmid DNA relaxation was assessed in 1% agarose gels by electrophoresis in 0.1 M Tris borate EDTA buffer (pH 8.0) at 2 V/cm for 16 h. Gels were visualized with UV illumination after staining with ethidium bromide (0.5 mg/mL). A further electrophoresis was run in the presence of 0.1 mg/mL ethidium bromide, in order to separate the nicked DNA from the relaxed topoisomers.
Oligonucleotide assays
A 202-bp PvuII/HindIII fragment of pSK DNA substrate [
32 P]-labeled at a single 3 0 -end, was prepared as described elsewhere [23] . Equal concentrations of LiTopIB were incubated with at least 1.5 mL of DNA containing a minimum of 100,000 cpm in 10 mM Tris-HCl buffer pH 7.5, 5 mM MgCl 2 , 5 mM DTT, 0.1 mM EDTA, 15 mg/mL bovine serum albumin, 50 mM KCl, and different concentrations of camptothecin, topotecan, SN-38, gimatecan and camptothecin-N-oxide in 1% DMSO. Following incubation for 2 min at room temperature, reactions were either stopped directly with 1% SDS or treated with 0.5 M NaCl for 1 h at 25 8C to force LiTopIB religation and then stopped with 0.5% SDS at indicated times. The samples were heated at 75 8C for an extra 15-min period, treated with proteinase K and subjected to doubleethanol precipitation prior to electrophoresis in a 16% polyacrylamide/7 M urea gel. Stabilized cleavage products were visualized with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
In situ sensitivity to camptothecin derivatives
For drug-induced protein-DNA complex determination, L. infantum promastigotes, previously labeled for 24 h with 0.5 mCi/mL [2- 14 C] thymidine, were exposed to different concentrations of camptothecin and its derivatives for 30 min, followed SDS/KCl method as previously described [20] . All assays included solvent controls. DNA fragments formation, as a percentage of total labeled DNA, was calculated as follows: [(dpm in SDS/KCl drug À dpm in SDS/KCl solvent)/(dpm total incorporation)] Â 100. Each experiment was run at least in triplicate. For each drug the concentration causing 50% of DNA to be cleaved (CC 50 ) was calculated from dose/response curves.
Results
Leishmanicidal effect of camptothecin and analogues
We have analyzed the effect of the specific TopIB inhibitors outlined in Fig. 1 on the proliferation rate of L. infantum-IFR1.4 promastigotes and amastigotes. Table 1 shows the IC 50 values obtained from dose-response plots, based on the percentage of infrared fluorescence signal at 708 nm, obtained for free-living promastigotes and amastigote-infected splenocytes, exposed for 48 h to several concentrations of the tested compounds in comparison to untreated controls. The IC 50 value obtained with miltefosine (a leishmanicidal alkylphospholipid) is also reported in Table as Table 1 , shows that gimatecan is the safest compound with a SI 48h value three fold higher than miltefosine and significantly higher than the other tested compounds.
In situ formation of cleavable complexes
The formation of enzyme-DNA adducts, in promastigotes exposed to camptothecin analogues, has been evaluated by protein precipitation with SDS. L. infantum promastigotes, grown in the presence of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-thymidine, have been exposed to increasing drugs concentrations over a period of 30 min. The percentage of labeled SDS/KCl precipitable complexes with respect to total labeled DNA has been determined using camptothecin as reference drug ( Fig. 2A) . Gimatecan displays the maximum DNA-cleaving potency (CC 50 = 0.02 mM) since a gimatecan concentration of 0.3 mM is enough to obtain 80% of cleaved DNA (Fig. 2C) . A camptothecin or topotecan concentration of 1 and 10 mM respectively is needed to obtain a comparable DNA breakage percentage ( Fig. 2A and B) . Camptothecin-N-oxide reaches the same percentage at a concentration of 90 mM (Fig. 2D) , whilst in the case of SN-38 the maximum concentration of cleaved DNA is 50% even at a concentration of 90 mM (Fig. 2E ).
LiTopIB inhibition by camptothecin and derivatives
The effect of the different compounds on the relaxation activity of LiTopIB has been monitored over time incubating 1 U of LiTopIB with 75 mM of each derivative in the presence of 0.5 mg of 37 8C pre-warmed supercoiled pSK DNA. Aliquots have been then taken at different time points, ranging from 0.2 to 15 min. As shown in Fig. 3A , in absence of the drug, the supercoiled substrate is fully processed after 0.2 min. Camptothecin and SN-38 inhibit the The inhibitory potency of the camptothecin derivatives on the relaxation activity of recombinant LiTopIB was also assessed after 30 sec as a function of drug concentrations (Fig. 3B) . Topotecan, camptothecin, gimatecan and SN38 have a comparable efficacy whilst larger camptothecin-N-oxide concentrations are required to have the same level of inhibition (Fig. 3B) .
Camptothecin derivatives poison LiTopIB
A cleavage-religation equilibrium assay has been carried out in order to assess the cleavage stabilization nature of these drugs as TopIB poisons. These compounds are expected to act stabilizing the cleavable complexes generated by the nicking action of the enzyme. Once the enzyme is attached to DNA and cuts one of its strands, camptothecin stabilizes the LiTopIB-DNA complex and hinders the religation of the nicked DNA [10] . A PvuII/HindIII fragment of pSK DNA has been incubated with 100 U of LiTopIB in presence of different drugs concentrations (0.1, 1, 10 and 100 mM).
The first lane of Fig. 4 shows that in absence of the drugs no signals of the cleaved oligo are observed, indicating that the religated/ uncleaved (R/U) equilibrium is shifted towards religation. In presence of SN-38, topotecan and gimatecan the equilibrium is shifted towards cleavage, since several cleaved bands (CL1, CL2 and CL3) are appearing due to the stabilization of the cleavable complexes. Gimatecan is the most powerful compound, since it stabilizes the enzyme-DNA complexes at concentrations of 0.1 mM. Camptothecin and SN-38 require a concentration 10-fold higher, whereas topotecan a 100-fold higher concentration to reproduce comparable effects. It is interesting to notice that topotecan is not able to trap the CL2 cleavable complex, likely due to a low residence time of the drug in this site or to a different cleavage pattern for topotecan in which CL2 is not a preferred site [24] . Fig. 5 shows a cleavage complex reversal assay comparing the stability of both LiTopIB-camptothecin-DNA and LiTopIB-gimatecan-DNA ternary complexes. The reversal of the LiTopIB cleavable complexes is much slower for gimatecan than for camptothecin. The effect of camptothecin persists for two minutes, whilst the gimatecan-stabilized complex can be detected up to 15 min. The long persistence time of gimatecan on the DNA cleaved site provides an explanation to its greater potency in inducing cell death. 
Discussion
One of the most problematic aspects of leishmaniases is the fast emergence of resistant strains against conventional drugs, which hinders the treatment and consequently, constant development of new therapeutic resources is required. In the present study, we have shown that gimatecan is a powerful growth inhibitor of L. infantum promastigotes that is even more lethal for its intracellular form (amastigote) ( Table 1 ). In addition, gimatecan is also shown to be a potent LiTopIB-poison.
In vitro results show that the relaxation activity of L. infantum DNA topoisomerase IB is inhibited by all the camptothecin derivatives, with the exception of camptothecin-N-oxide and irinotecan, within the nanomolar range (Fig. 2B) , suggesting that this enzyme is the potential target in camptothecin-treated Leishmania parasites. Gimatecan stabilizes the cleavable complexes at a concentration 10-fold lower than camptothecin, and of any other camptothecin derivatives (Fig. 4) . Moreover the gimatecan-stabilized complexes are slowly reverted in comparison with the ones stabilized by camptothecin (Fig. 5) . This fact may explain the enhanced leishmanicidal effect of gimatecan, since drug-induced DNA damage is directly proportional to the lifespan of the ternary complex. The slow reversal of the gimatecan-induced cleavable complexes is likely due to its 7-t-butoxyiminomethyl substitution, since this position has been shown to be important in other 7-modified camptothecin derivatives [25] . The long residence time of the gimatecan stabilized ternary complexes, is also in agreement with the long time that the LiTopIB relaxation activity remains hindered by this drug (Fig. 3A) and the greater potency of gimatecan in inducing SDS/KCl-precipitable DNA-topoisomerase complexes in vivo (Fig. 2) .
The leishmanicidal activity of the camptothecin derivatives has been validated on a model of mouse splenocytes infected with a L. infantum strain expressing IFP1.4, which permits to study the compounds under conditions that resemble those found in the animal, including the presence of the complete range of immune host cells, infected macrophages and fibroblasts [20] . For all the studied derivatives the sensitivity of the amastigote form is much higher than that of free-living promastigotes (Table 1) . This is not an unexpected result since many drugs with different intracellular targets have similar behavior [26] . However, irinotecan does not have leishmanicidal effect (up to 100 mM) in the splenocytes, suggesting that this compound is not metabolically hydrolyzed to SN-38 within the splenic explants.
A remarkable finding is the extraordinary power of gimatecan in all trials conducted both in vitro and ex vivo. This drug has a therapeutic selectivity index above 170, three times higher than miltefosine that is clinically used for the treatment of leishmaniasis (Table 1) . Furthermore, gimatecan presents a series of added values, which must be taken into consideration, as they substantially improve the therapeutic index obtained for this drug and make it interesting for the treatment of visceral leishmaniasis: (i) after oral administration the highest tissue levels are found in liver and spleen [27] ; (ii) the percentage of active lactone form in plasma is 80 to 100%, much higher than those of its analogues, topotecan, irinotecan and SN-38 estimated at ca. 20% for each [28, 29] ; (iii) a half-life of over 76.5 h, maintaining significant concentrations in plasma 7 days after the dose was given [28] ; (iv) Zhu et al. [28] have shown in cancer patients that after weekly administration of oral gimatecan at 1.2 mg/kg concentration for 3 weeks the gimatecan is tolerated and has favorable pharmacokinetic properties. Miltefosine, despite its drug safety, has a less desirable dosage regimen that involves the administration of 1.76 mg/kg/d for 28 days for an effective oral treatment of this cutaneous disease, resulting in difficulty of adherence to treatment of infected people in developing countries [30] ; (v) unlike other camptothecins the pharmacokinetics of the compound appears to be more favorable in humans than in mice [29] ; (vi) it has recently been shown that gimatecan is not affected by multidrug resistant protein 1 (MDR-1) efflux in tumor cell lines (responsible for resistance to camptothecin), which have an orthologous protein-coding gene in Leishmania [15] .
In conclusion, the present study indicates that all the here studied camptothecins with the exception of camptothecin-N-oxide, are Leishmania topoisomerase IB poisons in the low micromolar range, although gimatecan is the most efficient one and its excellent selectivity index suggest that this compound may be exploited as a potential drug candidate against visceral leishmaniasis.
